Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Digoxin
Drug ID BADD_D00668
Description Digoxin is one of the oldest cardiovascular medications used today.[A178225] It is a common agent used to manage atrial fibrillation and the symptoms of heart failure.[A178234] Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954.[L9143] This drug originates from the foxglove plant, also known as the _Digitalis_ plant[T610], studied by William Withering, an English physician and botanist in the 1780s.[A178237,A178240] Prior to this, a Welsh family, historically referred to as the _Physicians of Myddvai_, formulated drugs from this plant. They were one of the first to prescribe cardiac glycosides, according to ancient literature dating as early as the 1250s.[A178240]
Indications and Usage Digoxin is indicated in the following conditions: 1) For the treatment of mild to moderate heart failure in adult patients.[L9143] 2) To increase myocardial contraction in children diagnosed with heart failure.[L9143] 3) To maintain control ventricular rate in adult patients diagnosed with chronic atrial fibrillation.[L9143] In adults with heart failure, when it is clinically possible, digoxin should be administered in conjunction with a diuretic and an angiotensin-converting enzyme (ACE) inhibitor for optimum effects.[L9143]
Marketing Status approved
ATC Code C01AA05
DrugBank ID DB00390
KEGG ID D00298
MeSH ID D004077
PubChem ID 2724385
TTD Drug ID D02OZE
NDC Product Code 82685-202; 42385-101; 69205-201; 57664-437; 59651-436; 70518-2959; 70954-202; 10135-748; 69205-101; 16714-590; 52584-410; 71610-019; 82685-201; 16714-591; 0115-9811; 0115-9822; 50090-5642; 57664-441; 63187-740; 69238-1992; 59212-240; 59651-438; 66689-327; 70515-261; 45085-0101; 69205-202; 0143-1240; 71335-1052; 0143-1241; 50090-5862; 60429-100; 0404-9850; 0054-0057; 69238-1991; 69292-605; 70515-263; 0641-1410; 51927-0291; 51655-403; 59212-242; 59212-249; 60429-099; 70518-3124; 70518-3421; 0615-8202; 0641-6184; 70954-201; 59695-0001; 59695-0002; 55154-5882; 59651-437; 60687-551; 71335-9610; 0904-5921; 51662-1217; 55154-5106; 60687-540; 70515-260; 70515-262; 70954-200; 0781-3059; 0904-5922; 10135-747; 55742-123; 59695-0004
UNII 73K4184T59
Synonyms Digoxin | Lanacordin | Lanicor | Lanoxicaps | Dilanacin | Digacin | Digitek | Digoregen | Digoxina Boehringer | Boehringer, Digoxina | Digoxine Nativelle | Nativelle, Digoxine | Hemigoxine Nativelle | Nativelle, Hemigoxine | Mapluxin | Lanoxin | Lanoxin-PG | Lanoxin PG | Lenoxin
Chemical Information
Molecular Formula C41H64O14
CAS Registry Number 20830-75-5
SMILES CC1C(C(CC(O1)OC2C(OC(CC2O)OC3C(OC(CC3O)OC4CCC5(C(C4)CCC6C5CC(C7(C6(CCC7C8=CC(=O) OC8)O)C)O)C)C)C)O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Decreased appetite14.03.01.005; 08.01.09.0280.001547%
Adverse drug reaction08.06.01.0090.001842%Not Available
Disease recurrence08.01.03.0500.000211%Not Available
Obstructive airways disorder22.03.01.0110.000105%Not Available
Psychotic disorder19.03.01.002--
Renal impairment20.01.03.0100.000811%Not Available
Hypophagia19.09.01.004; 14.03.01.006; 07.01.06.0100.000105%Not Available
Chronic kidney disease20.01.03.0170.000263%
Spontaneous haematoma24.07.01.054; 01.01.03.0060.000105%Not Available
Supraventricular tachyarrhythmia02.03.03.014--Not Available
Treatment failure08.06.01.0170.000263%Not Available
Adverse reaction08.06.01.0180.000842%Not Available
Decreased vibratory sense17.02.07.0130.000105%Not Available
Low birth weight baby18.04.02.0030.000684%Not Available
Skin mass23.07.04.014--Not Available
Brain injury19.07.03.007; 17.11.01.0030.000158%Not Available
Acute kidney injury20.01.03.0160.005064%
Atrioventricular dissociation02.03.01.0120.000263%Not Available
Foetal growth restriction18.03.01.0020.000211%
Toxicity to various agents12.03.01.046--Not Available
Sinus node dysfunction02.03.03.0170.000579%
Multiple organ dysfunction syndrome08.01.03.0570.000211%
Cardiac aneurysm24.02.02.004; 02.04.02.0300.000105%Not Available
Cardiac failure chronic02.05.01.0090.000316%Not Available
Drop attacks17.05.02.016; 15.05.04.0180.000158%Not Available
Neonatal respiratory distress syndrome22.11.02.010; 18.04.10.0030.000105%Not Available
Wolff-Parkinson-White syndrome02.03.01.0160.000211%Not Available
Aneurysm ruptured24.02.01.0020.000316%Not Available
Live birth18.08.02.0070.000263%Not Available
Neonatal tachycardia18.04.07.009; 02.03.02.0260.000105%Not Available
The 9th Page    First    Pre   9 10    Next   Last    Total 10 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene